Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Initial urologic management of myelomeningocele.Urol Clin North Am. 2004; 31 (viii): 427-434
- Predictive value of urodynamic evaluation in newborns with myelodysplasia.JAMA. 1984; 252: 650-652
- Prognostic value of urodynamic testing in myelodysplastic patients. 1981.J Urol. 2002; 167 (discussion: 1054): 1049-1053
- Botulinum toxin injections for paediatric incontinence.Curr Opin Urol. 2005; 15: 264-267
- The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.Neurology. 2000; 55: S29-S35
- Human response to botulinum toxin injection: type B compared with type A.Neurology. 1997; 49: 189-194
- Botulinum toxin: dangerous terminology errors.J R Soc Med. 1993; 86: 493-494
- Molecular pharmacology of botulinum toxin and tetanus toxin.Annu Rev Pharmacol Toxicol. 1986; 26: 427-453
- Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.J Urol. 1988; 139: 919-922
- Effects of botulinum A toxin on the periurethral striated sphincter of the neurogenic bladder.J Urol (Paris). 1990; 96: 375-380
- Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.Eur Urol. 2009; 55: 705-711
Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol, in press.
- Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.Urology. 2006; 68: 1091-1096
- Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?.J Urol. 2000; 164: 692-697
- The Paris Consensus on Childhood Constipation Terminology (PACCT) group.J Pediatr Gastroenterol Nutr. 2005; 40: 273-275
- International system of radiographic grading of vesicoureteric reflux.Pediatr Radiol. 1985; 15: 105-109
- Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.Urology. 2005; 65: 37-41
- The role of ureter in the creation of Mitrofanoff channels in children.J Urol. 1997; 157: 635-637
- Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia.J Urol. 2004; 171 (discussion: 848): 845-848
- Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results.Urology. 2002; 59 (discussion: 327-328): 325-327
- Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.Urology. 2004; 63: 868-872
- Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients.J Urol. 1996; 155: 1023-1029
- Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.J Urol. 2005; 174 (discussion: 982-983): 977-982
- Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder.Eur Urol. 2004; 46: 784-791
- Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.Arch Phys Med Rehabil. 1990; 71: 24-26
- Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.Eur Urol. 2002; 42: 56-62
- Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity.Spinal Cord. 2002; 40: 599-600
This project has been supported by a research grant from Tehran University of Medical Sciences.
Abdol-Mohammad Kajbafzadeh, Hamid Arshadi and Farideh Nejat take the responsibility for data integrity and accuracy and both were involved in patient selection, management, and data acquisition. Saeed Safari and Sarah Jamali were involved in study management and conducting blind allocation. They also reviewed the manuscript content for intellectual content. Peiman Habibollahi analyzed and interpreted the data and drafted the manuscript.